2023-503440-14-00招募中1 期
A Multi-arm Phase 1b Study of Teclistamab With Other Anticancer Therapies in Participants With Multiple Myeloma
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 43
- 试验地点
- 5
研究概览
简要总结
暂无简介。
入排标准
- 年龄范围
- 18 years 至 65+ years（65+ Years, 18-64 Years）
- 接受健康志愿者
- 是
入选标准
- 未提供
排除标准
- 未提供
研究者
CTIS Point of Contact
Scientific
Janssen - Cilag International
研究点 (5)
Loading locations...
相似试验
招募中
2 期
An open label, multicenter, Phase 2, pilot study, evaluating early treatment with bispecific T-cell redirectors (teclistamab and talquetamab) in the therapy of newly diagnosed high -risk multiple myelomaMultiple Myeloma2024-514016-26-00Fundacion Pethema30
招募中
2 期
A Study Evaluating Different Immunotherapies (LAG-3 and PD-1 With or Without TIGIT, Compared to PD-L1 Alone) in Participants With Untreated Locally Advanced Metastatic Urothelial Cancer2023-504027-78-00F. Hoffmann-La Roche AG150
招募中
2 期
Safety and efficacy of IMCgp100 versus Investigator’s Choice in advanced uveal melanoma2024-517290-24-00Immunocore Limited96
招募中
2 期
A Study of Tislelizumab in Combination With Investigational Agents in Participants With Non-Small Cell Lung Cancer.Non-small Cell Lung Cancer2022-502738-18-00Beigene Ltd., Beigene Ltd., Beigene Ltd.22
已完成
2 期
Phase II, Open-Label Study of preliminary efficacy of Sitravatinib in Combination with Tislelizumab in Patients with Metastatic Uveal Melanoma with liver metastases.2024-519451-29-00Grupo Espanol Multidisciplinar De Melanoma16